Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428190500403144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Blood Adv
February 2025
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with newly diagnosed AML using data from a nationwide electronic health record-derived deidentified database. Patients were categorized based on their diagnosis date relative to venetoclax approval, as pre-novel therapy era (Pre era; 2014-2018; n = 2998) or post-novel therapy era (Post era; 2019-2022; n = 2098).
View Article and Find Full Text PDFObecabtagene Autoleucel: First Approval.
Mol Diagn Ther
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Obecabtagene autoleucel (AUCATZYL) is a CD19-directed genetically modified autologous T cell immunotherapy which is being developed by Autolus for the treatment of hematological cancers and systemic lupus erythematosus. In comparison with other chimeric antigen receptor T (CAR T) therapies, obecabtagene autoleucel has a fast off-rate binder for CD19. Obecabtagene autoleucel received approval following positive results from the FELIX phase I/II trial in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and it is the first CAR T therapy that does not have mandatory Risk Evaluation Mitigation Strategy monitoring requirements.
View Article and Find Full Text PDFLeukemic cells infiltrate the ovaries without damaging ovarian reserve in an acute myeloid leukemia mouse model.
Endocrinology
January 2025
Olson Center for Women's Health, Department of Obstetrics and Gynecology, College of Medicine, University of Nebraska Medical Center, Omaha, NE.
Leukemia is one of the most common cancers in prepubertal girls and adolescents, with advances improving survival rates. However, treatments like chemotherapy and radiation are highly gonadotoxic, often causing ovarian insufficiency, early menopause, infertility, and endocrine disorders. Fertility preservation for young female cancer patients, especially prepubertal girls without mature germ cells, relies heavily on ovarian tissue cryopreservation.
View Article and Find Full Text PDFCost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.
Ann Hematol
January 2025
FROM, Fondazione per la Ricerca Ospedale di Bergamo, Bergamo, Italy.
Treatment of polycythemia vera (PV) aims to maintain hematocrit on target to reduce risk of thrombotic complications, while preventing disease progression to myelofibrosis (MF) and acute myeloid leukemia (AML). This analysis evaluated cost-effectiveness of adding ropeginterferon alfa-2b (ropegIFNα) to phlebotomy in patients with low-risk PV (those younger than 60 years without prior thrombosis), compared to phlebotomy alone. We combined a 12-month decision tree with a semi-Markov cohort model comparing ropegIFNα to the standard treatment from the Austrian healthcare system perspective over 30 years.
View Article and Find Full Text PDFFocus on the Holdrinet index: Toward blast quantification by flow cytometry.
Cytometry B Clin Cytom
January 2025
Université Grenoble Alpes, Laboratory of Immunology, CHU Grenoble Alpes, Grenoble, France.
Blast quantification in the bone marrow (BM) is crucial for evaluating myeloid neoplasms, with cytomorphology being the only recognized analysis. The CD34 myeloid cell (CD34M) count by flow cytometry is promising but impaired by BM hemodilution. A modified version of the Holdrinet index (mHI) is routinely used to assess it, though not yet validated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!